Abstract:Sjogren’s syndrome (SSj) is a systemic disease with autoimmune pathogenesis, with prevalent involvement of the lacrimal and salivary exocrine glands, classified as primary or secondary on the basis of the association with other rheumatic diseases.The epidemiological data in the literature are variable due to the heterogeneity of the populations examined and the different classification criteria used.In a recent systematic review by Baodon Qin et al. In a recent systematic review by Baodon Qin et al. the average incidence rate was 7 cases every 100,000 people/year (range 5-9) with higher values in the Caucasian and Asian populations, with a women/men ratio of 9.3 (95% CI 3.35 to 13.18), while the prevalence rate was 61 cases per 100,000 inhabitants (range 10-90) with a female/male ratio of 10.7 (95% CI 7.35-15.62).The aim of the study was to estimate the prevalence rate of primary SSj in real-life, through analysis of administrative data.An epidemiological research was carried out as at 31 December 2020, through the analysis of all adult patients residing in Piedmont (northwest of Italy) with exemption code (EC) for SSj (code 030) and any association with other ECs for rheumatological pathologies or for pathologies considered according to the 2016 EULAR/ACR classification criteria; specifically, the EC were considered for rheumatoid arthritis, ulcerative colitis and Crohn’s disease, chronic hepatitis (active), HIV infection, affected subjects from malignant neoplastic pathologies, tumors of uncertain behavior, systemic lupus erythematosus, Hashimoto’s thyroiditis, undifferentiated connective tissue disease; mixed cryoglobulinemia, antiphospholipid antibody syndrome (primary form), primary and familial amyloidosis, hereditary/familial autoinflammatory syndromes, microscopic polyangiitis, polyarteritis nodosa, sarcoidosis, dermatomyositis, polymyositis, mixed connective tissue disease, progressive systemic sclerosis.There were 3889 patients with EC for SSj as at 31 December 2020, of which 2611 with active EC.The number of assisted people alive with the aforementioned exemption was 2601, while those with other exemptions in the list were 1020. Of these patients, 1581 had only the exemption from code 030 as at 31 December 2020; the distribution of the other pathologies analyzed is shown in the tables below (Table 1).Of the total number of patients with active exemption, 2442 were female, while 159 were male, with a female/male ratio of 15.3; the distribution by gender is shown in Figure 1.Considering that the Piedmont population on 31 December 2020 was 4 274 945 inhabitants (ref: National Institute of Statistics), the estimated prevalence rate was 4.7 cases per 10 000 inhabitants.Table 1.Distribution of EC in patients residing in Piedmont as at 31/12/2020Diseases with ECN of patientsRheumatoid Arthritis250Ulcerative colitis and Crohn’s disease18chronic hepatitis52HIV infection2Systemic Lupus Erythematosus122Subjects affected by malignant neoplastic pathologies330Hashimoto’s thyroiditis280Undifferentiated Connective Tissue Sisease86Mixed Cryoglobulinemia6Antiphospholipid Antibody Syndrome8Primary And Familial Amyloidosis3Hereditary/Familial Autoinflammatory Syndromes1Microscopic Polyangiitis2Polyarteritis Nodosa1Sarcoidosis5Dermatomyositis2Polymyositis5Mixed connective tissue disease25Progressive systemic sclerosis56Figure 1.Distribution by gender of patients residing in Piedmont with exemption for Sjogren’s Syndrome. F: Female; M: MaleThis research has some limitations, including the retrospective design and the use of administrative data which may be affected by the aforementioned difficulty of classification as well as incorrect attributions of exemption, both for SSj and for associated pathologies.Our research highlights a number of patients with primary SSj lower than the prevalence figure that defines a rare disease, i.e. a prevalence of less than 5 cases per 10,000 inhabitants.Further studies are needed to confirm these preliminary data.[1]Baodong Qin et al. Ann Rheum Dis. 2015 Nov;74(11):1983-9.NIL.None Declared.

Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study

Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis

Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome

Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study

A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience

Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study

Primary Sjögren’s Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development

Update on the pathophysiology and treatment of primary Sjögren syndrome

The association between primary Sjogren's syndrome and non-Hodgkin's lymphoma: a systematic review and meta-analysis of cohort studies

Vitamin D Deficiency in Primary Sjögren's Syndrome: Association with Clinical Manifestations and Immune Activation Markers

A Pilot Monocentric Exploratory Study

Mortality in Patients with Primary Sjögren’s Syndrome: a Systematic Review and Meta-Analysis

Long-term survival analysis of patients with primary Sjögren's syndrome in China: A multicenter retrospective cohort study

POS0998-HPR THE EPIDEMIOLOGY OF PRIMARY SJOGREN’S SYNDROME: IS IT A RARE DISEASE?

Utilisation of primary healthcare services by Sjögren's syndrome patients in the Community of Madrid and associated factors: a population-based cross-sectional study

A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Profiles of peripheral B cell subsets in a cohort of primary Sjögren's syndrome patients and their potential clinical significance

Lymphoma in Sjögren's syndrome: no need for repetitive screening ultrasounds of the major salivary glands and neck in asymptomatic patients